Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARSYNAL-FC: Antivirals for Acute Symptomatic RSV
NCT06488300Phase 2Recruiting
- Sponsor
- University of Oxford
- Start
- Jul 2024
- Primary completion
- Jan 2027
- Modality
- Orthosteric Ligands, RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of ribavirin, molnupiravir and favipiravir in respiratory syncytial virus infection (RSV) (4 arms), sponsored by University of Oxford. Primary endpoint: Rate of viral clearance. Started Jul 2024; status: recruiting.
02
Drugs
ribavirinmolnupiravirfavipiravir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06488300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06488300.